Recombinant human IFN-β protein - Bioactive cytokine

Recombinant cytokine, source: CHO cells

ABOUT

Human IFN-β protein - Mammalian cell-expressed, tag-free, carrier-free

Recombinant human IFN-β is a high-quality and biologically active cytokine, validated using proprietary IFN-α/β reporter cells. This member of the type I interferon family is produced in CHO cells to ensure protein glycosylation and bona fide 3D structure.

Recombinant human IFN-β can be used together with HEK-Blue™ IFN-α/β cells for screening molecules that inhibit IFN-β signaling, such as Anifrolumab, a monoclonal antibody targeting the IFNAR subunits of the IFN-β receptor (see figures).
 

Key features

  • Each lot is validated using HEK-Blue™ IFN-α/β cells
  • Endotoxin ≤ 1 EU/µg
  • 0.22 µm sterile-filtered

Applications

  • Standard for IFN-β detection and quantification assays
  • Screening and release assays for antibodies blocking IFN-β signaling
  • Screening and release assays for engineered IFN-β

 

Interferon beta (IFN-β) is an important member of the type I IFN family. It is an important anti-viral cytokine that also plays anti-proliferative and immunomodulatory roles.

More details

All InvivoGen products are for internal research use only, and not for human or veterinary use.

IFN-β signaling and biological functions
IFN-β signaling and biological functions

SPECIFICATIONS

Specifications

Source
CHO cells
Species
Human
Synonyms
IFN-beta
Fibroblast interferon
Accession sequence

P01574

Protein size
166 a.a. (M22-N187)
Molecular weight
~ 20-23 kDa (SDS-PAGE)
International units (IU)

>108 IU/mg*

Carrier
Carrier-free
Tag
Tag-free
Purity
≥ 95% (SDS-PAGE)
Solubility

100 μg/ml in water

Formulation buffer

10 mM Sodium Acetate (pH 4.5), 5% trehalose, 5% mannatol, and 0.01% Tween-80

Appearance (form)
Lyophilized
Reconstitution buffer
Endotoxin-free water (provided)
Sterility

0.22 µm filtration

Endotoxin

The absence of bacterial contamination (e.g. lipoproteins and endotoxins) has been confirmed using HEK-Blue™ TLR2 and HEK‑Blue™ TLR4 cells.

Applications

Cellular assays (tested), ELISA

Quality control

Each lot is functionally tested and validated.

Additional information

*Please refer to the corresponding Certificate of Analysis (CoA) for the exact value.

CONTENTS

Contents

  • Product: 
    Recombinant human IFN-β
  • Cat code: 
    rcyc-hifnb
  • Quantity: 
    20 µg
Includes:

1.5 ml endotoxin-free water

Shipping & Storage

  • Shipping method:  Room temperature

    • Storage:

    • -20°C
    Stability: -20°C for up to 1 year

    Caution:

    • Avoid repeated freeze-thaw cycles

Details

IFN-β background

IFN-β belongs to the type I  interferon (IFN) family. IFN-β and IFN-α are the most broadly expressed type I IFNs. They are important anti-viral cytokines that also play anti-proliferative and immunomodulatory roles [1, 2].

IFN-β and all of the IFN-α subtypes bind to a heterodimeric transmembrane receptor composed of the subunits IFNAR1 and IFNAR2, which are associated with the tyrosine kinases Tyk2 and Jak1 (Janus kinase 1), respectively. These kinases phosphorylate STAT1 and STAT2, which then dimerize and interact with IFN regulatory factor 9 (IRF9), leading to the formation of the ISGF3 complex. ISGF3 binds to IFN-stimulated response elements (ISRE) in the promoters of IFN-stimulated genes (ISG) to regulate their expression.
 

Relevance for therapeutics development

Multiple sclerosis (MS) is a multifactorial chronic demyelinating disease that causes serious damage in the central nervous system. There is increasing evidence that Epstein-Barr Virus (EBV) infection is involved in the disease processes [2]. IFN-β therapies are a major class of drugs approved by the U.S. Food and Drug Administration (FDA) to treat relapsing/remitting MS. These include recombinant human IFN-β1a (e.g., Rebif), pegylated IFN-β1a (Plegridy), and recombinant human IFN-β1b (e.g., Betaferon). Although their mode of action is not fully elucidated, IFN-β therapies could counterweigh the EBV signature at multiple points by sustaining EBV-specific B cell responses and reducing the number of circulating EBV-specific CD8+ T cells to restrain excessive and damaging lytic responses [2].

Despite their protective effects, studies have shown that aberrant expression of the type I IFNs can elicit autoimmune disorders, such as interferonopathies and SLE (systemic lupus erythematosus). Recent evidence also implicates type I IFN-dependent signaling as a key inflammatory driver in non-autoimmune diseases [3].
Anifrolumab is a monoclonal antibody that targets the type I IFN receptor subunit 1 (IFNAR1) and blocks the type I IFN signaling. It is approved by the FDA as an add-on therapy for moderately to severely active SLE [4].

 

References:

1. McNab, F., et al., 2015. Type I interferons in infectious disease. Nat Rev Immunol. 15(2):87-103.
2. Belluci., G., et al., 2023. The value of Interferon β in multiple sclerosis and novel opportunities for its anti-viral activity: a narrative literature review. Front Immunol. 14:1161849.
3. Crow MK, Ronnblom L., 2019. Type I interferons in host defence and inflammatory diseases. Lupus Sci Med. 6(1):e000336.
4. U.S. Food and Drug Administration (FDA) (Report). 2022. Advancing Health Through Innovation: New Drug Therapy Approvals 2021.

You may also need

CUSTOMER SERVICE & TECHNICAL SUPPORT

Question about this product ?